NextCure, Inc.NXTCNASDAQ
Loading
Year-over-year research & development expense growth
Percentile
P52
Within normal range
vs 2Y Ago
0.7x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 4.99% |
| Q3 2025 | -74.53% |
| Q2 2025 | 205.10% |
| Q1 2025 | -11.30% |
| Q4 2024 | 1.51% |
| Q3 2024 | -29.38% |
| Q2 2024 | 8.95% |
| Q1 2024 | -3.63% |
| Q4 2023 | 7.42% |
| Q3 2023 | -18.12% |
| Q2 2023 | 15.45% |
| Q1 2023 | -9.16% |
| Q4 2022 | -5.22% |
| Q3 2022 | 5.48% |
| Q2 2022 | -14.64% |
| Q1 2022 | 22.50% |
| Q4 2021 | -9.80% |
| Q3 2021 | 13.83% |
| Q2 2021 | -3.56% |
| Q1 2021 | 2.31% |
| Q4 2020 | -4.98% |
| Q3 2020 | 14.47% |
| Q2 2020 | 5.22% |
| Q1 2020 | -7.19% |
| Q4 2019 | 31.56% |
| Q3 2019 | 13.35% |
| Q2 2019 | 17.35% |
| Q1 2019 | 4.24% |
| Q4 2018 | 27.64% |
| Q3 2018 | 10.40% |
| Q2 2018 | 5.32% |
| Q1 2018 | 0.00% |